Robert Renninger serves as Chief Financial Officer at Athira Pharma, Inc., where they oversee executive responsibilities. Since joining the company, Robert Renninger has executed 8 insider transactions totaling $2.9K, demonstrating a bearish approach to their equity position. Their most recent transaction on Jan 2, 2026 involved selling 297 shares valued at $2.0K.
Robert Renninger currently holds 12,857 shares of Athira Pharma, Inc. (ATHA), valued at approximately $0. This represents their equity stake as Chief Financial Officer.
Based on SEC Form 4 filings, Robert Renninger has been a net seller of ATHA stock. They have purchased $0 and sold $2.9K worth of shares.
Robert Renninger's most recent insider trade was on Jan 2, 2026, when they sold 297 shares at $6.88 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Dec 31, 2025 | ATHA | $0 | Option Exercise | 1,236 | $N/A | Discretionary |
| Dec 24, 2025 | ATHA | $0 | Award | 34,358 | $N/A | Discretionary |
| Nov 18, 2025 | ATHA | $2.3K | Award | 1,000 | $2.31 | Discretionary |
| Jul 1, 2025 | ATHA | $840 | Sale | 2,897 | $0.29 | Discretionary |
| Jun 30, 2025 | ATHA | $0 | Option Exercise | 12,359 | $N/A | Discretionary |
| May 19, 2025 | ATHA | $2.3K | Award | 10,000 | $0.23 | Discretionary |